Holen Sie sich die Stockscreener-App
10.46
0.65%
-0.08
Schlusskurs vom Vortag:
$10.54
Offen:
$10.52
24-Stunden-Volumen:
2.92M
Relative Volume:
0.79
Marktkapitalisierung:
$1.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-766.97M
KGV:
-1.3655
EPS:
-7.66
Netto-Cashflow:
$-646.43M
1W Leistung:
+18.60%
1M Leistung:
+26.78%
6M Leistung:
-38.65%
1J Leistung:
-75.79%
1-Tages-Spanne:
$9.93
$10.63
1-Wochen-Bereich:
$8.29
$10.78
52-Wochen-Spanne:
$7.48
$44.55
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.43 | 1.40B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Norges Bank Makes New $12.74 Million Investment in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (NYSE:BHVN) Trading Up 8.8%Still a Buy? - MarketBeat
Responsive Playbooks and the BHVN Inflection - news.stocktradersdaily.com
Biohaven Ltd. $BHVN Position Lowered by Panagora Asset Management Inc. - MarketBeat
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders - MSN
Why Biohaven Ltd. stock could rally in 2025Jobs Report & Weekly Consistent Profit Watchlists - Newser
HC Wainwright Comments on Biohaven FY2029 Earnings - MarketBeat
Will Biohaven Ltd. Common Shares stock beat international competition2025 Institutional Moves & Weekly Setup with High ROI Potential - Newser
Will Biohaven Ltd. stock beat EPS estimatesJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Does Biohaven Ltd. stock trade at a discount to peersWeekly Trend Summary & Stock Portfolio Risk Management - Newser
Is Biohaven Ltd. Common Shares stock dividend growth reliableJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Biohaven (NYSE:BHVN) Shares Gap DownTime to Sell? - MarketBeat
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% - sharewise.com
Why Biohaven Ltd. Common Shares stock signals breakout potentialMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Biohaven to Neutral From Buy, Adjusts Price Target to $11 From $30 - marketscreener.com
Biohaven (BHVN) Receives Downgrade and Price Target Cut by HC Wa - GuruFocus
Biohaven downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
JPMorgan Chase & Co. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Capital Fund Management S.A. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Is Biohaven Ltd. Common Shares stock a defensive play amid uncertaintyPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Why Biohaven Ltd. stock appeals to dividend seekersJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - Newser
Why Is Biohaven Ltd. (BHVN) Stock Down Today? - Meyka
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
What downside risks could hit Biohaven Ltd. Common Shares stockWeekly Trade Recap & Pattern Based Trade Signal System - Newser
Biohaven (BHVN): Evaluating Valuation After UBS Downgrade and Shifting Analyst Sentiment - simplywall.st
Biohaven Ltd. $BHVN Stake Boosted by Geode Capital Management LLC - MarketBeat
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost - Yahoo Finance
Why Biohaven Ltd. Common Shares stock is a strong analyst pickCEO Change & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
The Bull Case For Biohaven (BHVN) Could Change Following Recent Analyst Downgrades - simplywall.st
RSI Check: Why retail investors favor Biohaven Ltd. stockM&A Rumor & Consistent Profit Trading Strategies - moha.gov.vn
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - AOL.com
Can Biohaven Ltd. stock outperform in 2025 bull market2025 Market WrapUp & Long Hold Capital Preservation Plans - moha.gov.vn
UBS Downgrades Biohaven (BHVN) - MSN
Biohaven downgraded to Neutral from Buy at UBS - MSN
Understanding the Setup: (BHVN) and Scalable Risk - news.stocktradersdaily.com
UBS Downgrades Biohaven (BHVN) and Lowers Price Target | BHVN St - GuruFocus
UBS downgrades Biohaven stock to Neutral on pipeline setbacks By Investing.com - Investing.com Nigeria
UBS Downgrades Biohaven to Neutral From Buy, $11 Price Target - MarketScreener
UBS downgrades Biohaven stock to Neutral on pipeline setbacks - Investing.com
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges - TipRanks
Biohaven (NYSE:BHVN) Stock Price Down 3.2%Here's Why - MarketBeat
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" - Finviz
Assessing Biohaven (BHVN) Valuation Following $175 Million Equity Offering and Underwriter Changes - simplywall.st
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):